Fifth Third Wealth Advisors LLC Trims Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Fifth Third Wealth Advisors LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 79.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,135 shares of the medical device company's stock after selling 23,511 shares during the quarter. Fifth Third Wealth Advisors LLC's holdings in DexCom were worth $477,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Jennison Associates LLC boosted its holdings in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock valued at $76,659,000 after acquiring an additional 739,000 shares during the period. Canada Pension Plan Investment Board boosted its stake in DexCom by 189.1% during the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock worth $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock worth $25,967,000 after purchasing an additional 369,587 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DexCom stock traded down $0.46 during trading hours on Friday, hitting $84.38. 5,134,065 shares of the company's stock traded hands, compared to its average volume of 3,952,632. The stock has a market capitalization of $32.96 billion, a price-to-earnings ratio of 50.53, a PEG ratio of 2.00 and a beta of 1.12. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a fifty day simple moving average of $78.17 and a 200-day simple moving average of $78.22.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research reports. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group upped their price target on DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. JPMorgan Chase & Co. raised their price objective on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Oppenheimer decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.29.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.